GLP-1 Market
LLY $1157.08 ▼ -2.3% NVO $37.91 ▼ -1.0% PFE $28.52 ▼ -0.7% VKTX $32.60 ▲ +2.5% KLRA $11.42 ▲ +3.9% GPCR $31.27 ▼ -4.3% RHHBY $51.91 ▼ -0.7%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

DR10624

DR10624

Company
Zhejiang Doer Biologics Co., Ltd.
Mechanism
Mechanism not yet reported
Route
Injectable
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Oct 1, 2026

Trial details
  • Completed NCT NCT05378893

    A First in Human (FIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DR10624

    Not yet reported Zhejiang Doer Biologics Co., Ltd. 153 participants Est. completion 2025-01-31 1 site Stand-alone
    Other conditions: Healthy, Obesity, Metabolically
    View official trial listing →
  • Completed NCT NCT06555640

    A Phase II Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia

    Not yet reported Zhejiang Doer Biologics Co., Ltd. 79 participants Est. completion 2025-08-29 35 sites Stand-alone
    Other conditions: Severe Hypertriglyceridemia
    View official trial listing →
  • Active, not recruiting NCT NCT07024212

    Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD Subjects

    Not yet reported Zhejiang Doer Biologics Co., Ltd. 110 participants Est. completion 2026-09-30 4 sites Stand-alone
    MASLD
    View official trial listing →
  • Enrolling by invitation NCT NCT07050134

    A Trial to Evaluate the Efficacy and Safety of DR10624 in Patients With Hypertriglyceridemia and Carotid Atherosclerotic Plaque

    Not yet reported Junbo Ge 40 participants Est. completion 2027-07-05 4 sites
    Other conditions: Hypertriglyceridemia, Carotid Atherosclerotic Plaques
    View official trial listing →
  • Not yet recruiting NCT NCT07680829

    A Phase 3 Trial of DR10624 Versus Placebo in Patients With Severe Hypertriglyceridemia

    Not yet reported Zhejiang Doer Biologics Co., Ltd. 378 participants Est. completion 2030-10 2 sites Stand-alone
    Other conditions: Severe Hypertriglyceridemia
    View official trial listing →
  • Not yet recruiting NCT NCT07693777

    A Phase III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia

    Not yet reported Zhejiang Doer Biologics Co., Ltd. 480 participants Est. completion 2029-12-05 1 site Stand-alone
    Other conditions: Severe Hypertriglyceridemia (sHTG), Hypertriglyceridemia
    View official trial listing →
  • Not yet recruiting NCT NCT07848880

    A Phase 2 Study to Evaluate the Efficacy and Safety of DR10624 in Subjects With Moderate Hypertriglyceridemia and Diabetic Kidney Disease

    Not yet reported Zhejiang Doer Biologics Co., Ltd. 315 participants Est. completion 2029-03 2 sites Stand-alone
    Other conditions: Hypertriglyceridemia
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: DR10624, DR10624 Injection

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.